𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung

✍ Scribed by Rudolf A. Joss; Jean-Paul Obrecht; Walter F. Jungi; Pierre Alberto; Christian Sauter; Franco Cavalli

Publisher
Springer
Year
1984
Tongue
English
Weight
163 KB
Volume
13
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

✦ Synopsis

Twenty-five patients with measurable small cell lung cancer relapsing after first-line chemotherapy were treated with vindesine 3 mg/m2 IV on days 1 and 8 and hexamethylmelamine 100 mg/m2 PO on days 1-14, repeated every 3 weeks. Among 18 fully evaluable patients there was 1 partial remission lasting for 111 days. Two patients had disease stabilization for 127 and 152 days, respectively. Fifteen patients had disease progression. The treatment was well tolerated, myelosuppression being the major side-effect.

πŸ“œ SIMILAR VOLUMES

Therapeutic efficacy and pharmacokinetic
Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma
✍ Joachim Z. Fuks; Merrill J. Egorin; Joseph Aisner; David A. Echo; Stanley Ostrow πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 480 KB

Twenty-nine patients with non-small cell lung cancer refractory to prior therapy were treated with either vindesine (VDS) alone (3 mg/m2 every week) or the combination of VDS plus cisplatin (DDP) (100 mg/m2 every 28 days). Serial blood and urine samples were collected to assess the pharmacokinetics

Phase II study of recombinant beta inter
Phase II study of recombinant beta interferon in patients with advanced non-small-cell lung carcinoma
✍ Ettinger, David S. ;Harwood, Kerry πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 238 KB

Eighteen patients with advanced non-smallcell lung cancer (NSCLC) received recombinant beta interferon, 90 million units three times weekly. No complete or partial responses were seen. Five patients had stable disease for several months. Most patients experienced some toxicity, most commonly fever a

Phase II trial of vindesine and VP16-213
Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer
✍ Simon G. Allan; Anna Gregor; Michael A. Cornbleet; Robert C. F. Leonard; John F. πŸ“‚ Article πŸ“… 1984 πŸ› Springer 🌐 English βš– 320 KB

Forty-three previously untreated patients, all of whom had poor-prognosis small cell lung cancer and/or were greater than 65 years old, received treatment with vindesine and VP16-213. Thirteen patients had limited disease and 30 extensive disease. Response rates (CR + PR) of 86% (CR 29%) and 66% (CR

A phase II clinical study of mAMSA in sm
A phase II clinical study of mAMSA in small cell carcinoma of the lung
✍ P. J. Dady; A. -P. Sappino; A. Rudd; I. E. Smith πŸ“‚ Article πŸ“… 1981 πŸ› Springer 🌐 English βš– 167 KB

Thirteen patients with small cell carcinoma of the bronchus that had become resistant to conventional chemotherapy were given 4'-(9-acridinylamino)methanesulphon-m-anisidide (mAMSA) at a dose of 90 or 120 mg/m2 at 3-week intervals. Twenty percent of the courses at 90 mg/m2 produced marked myelosuppr